Emerging microbiome market – unlocking new frontiers [Yahoo! Finance]
Seres Therapeutics, Inc. (MCRB)
Last seres therapeutics, inc. earnings: 11/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.serestherapeutics.com
Company Research
Source: Yahoo! Finance
Recent breakthroughs in microbiome research coupled with the recent approvals of microbiome-based therapies in the US - Ferring Therapeutics' Rebyota and Seres Therapeutics' Vowst - are expected to further accelerate the integration of microbiome treatments into clinical settings. As research into microbiome medicine advances, more therapeutic and commercial opportunities are anticipated to arise, driving the industry forward. Although at the moment biotechs are leading the charge in pipeline development, larger pharmaceutical companies are expected to become more involved once more successful microbiome therapies are ready to emerge. Their involvement may take the form of acquisitions, strategic partnerships, licensing agreements, and other collaborative efforts, which will further fuel market growth. To capture physicians' opinions and perspectives on microbiome-based therapies, leading data and analytics company GlobalData fielded a survey of 280 physicians from April to A
Show less
Read more
Impact Snapshot
Event Time:
MCRB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MCRB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MCRB alerts
High impacting Seres Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MCRB
News
- Seres Therapeutics, Inc. (NASDAQ: MCRB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $10.00 price target on the stock.MarketBeat
- Seres Therapeutics to Participate in Cantor 2024 Global Healthcare ConferenceGlobeNewswire
- Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) [Yahoo! Finance]Yahoo! Finance
- Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)GlobeNewswire
- After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB) [Yahoo! Finance]Yahoo! Finance
MCRB
Earnings
- 8/13/24 - Beat
MCRB
Sec Filings
- 9/12/24 - Form DEFA14A
- 9/12/24 - Form 8-K
- 8/26/24 - Form DEFM14A
- MCRB's page on the SEC website